Article

Preparation and evaluation of blank and doxorubicin loaded poly (acrylic acid) microspheres for embolization

  • Li-ying GUO ,
  • Xiao-xin LIU ,
  • Zi-yuan LI ,
  • Xiao-ya QIN ,
  • Ze-yang FAN ,
  • Zhen-zhen LI ,
  • Hai-tao GUAN ,
  • Li SONG ,
  • Ying-hua ZOU ,
  • Tian-yuan FAN
Expand
  • 1. The State Key Laboratory of Natural and Biomimetic Drugs, Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, Peking University School of Pharmaceutical Sciences, Beijing 100191, China
    2. Department of Interventional Radiology and Vascular Surgery, Peking University First Hospital, Beijing 100034, China

Received date: 2018-05-02

  Online published: 2018-12-18

Supported by

Supported by the National Natural Science Foundation of China(81571779)

Abstract

Objective: To prepare ion exchange doxorubicin-loaded poly (acrylic acid) microspheres (DPMs) and evaluate the properties of these chemoembolic agents.Methods:Poly (acrylic acid) microspheres (PMs) without drug were prepared by inverse suspension polymerization method and then doxorubicin was loaded by ion exchange mechanism to prepare DPMs. Optical microscope was used to investigate the morphology and particle size distribution of PMs and DPMs; fluorescence microscope and confocal microscope were used to observe the distribution of doxorubicin after drug loading. Elasticities of both the microspheres were evaluated by texture analyzer. High performance liquid chromatography (HPLC) method was established to determine the drug loading behavior of PMs and releasing behavior of DPMs. The in vivo embolic property was evaluated by embolizing the hepatic artery of a rabbit with 0.1 mL of DPMs.Results:PMs and DPMs were both spherical in shape, smooth in surface and dispersed well. Doxorubicin was mainly in the outer area inside of DPMs and distributed evenly. The average particle size of PMs and DPMs were (283±136) μm and (248±149) μm, respectively. PMs and DPMs both had good compression ability with the Young’s modulus of (62.63±1.65) kPa and (93.94±1.10) kPa separately. PMs reached the drug loading balance at 12 h, and the entrapment efficiency was greater than 99%. Drug loading of PMs in doxorubicin solution at the concentration of 5.0 g/L and 12.5 g/L was (19.78±0.27) g/L and (49.45±0.37) g/L, respectively. Doxorubicin released slowly from DPMs in PBS and the accumulative release percentages of DPMs with corresponding drug loading were 6.82%±0.02% and 2.83%±0.10% after 24 h, respectively. Arterial angiograms showed that the hepatic artery of the rabbit was successfully embolized with DPMs.Conclusion:DPMs with good performance of loading doxorubicin could be a potential embolic agent for transcatheter arterial chemoembolization.

Cite this article

Li-ying GUO , Xiao-xin LIU , Zi-yuan LI , Xiao-ya QIN , Ze-yang FAN , Zhen-zhen LI , Hai-tao GUAN , Li SONG , Ying-hua ZOU , Tian-yuan FAN . Preparation and evaluation of blank and doxorubicin loaded poly (acrylic acid) microspheres for embolization[J]. Journal of Peking University(Health Sciences), 2018 , 50(6) : 1070 -1077 . DOI: 10.3969/j.issn.1671-167X.2018.06.023

References

[1] 赵成如, 史文红, 金刚 . 医用介入栓塞材料[J]. 中国医疗器械信息, 2007,13(8):1-6.
[2] 金雪锋, 许颖, 沈晓兰 , 等. 载药动脉栓塞微球DC Bead TM研究进展 [J]. 药学与临床研究, 2012,20(4):319-325.
[3] Gomes AS, Monteleone PA, Sayre JW , et al. Comparison of triple-drug transcatheter arterial chemoembolization (TACE) with single-drug TACE using doxorubicin-eluting beads: long-term survival in 313 patients[J]. AJR Am J Roentgenol, 2017,209(4):722-732.
[4] Verret V, Namur J, Ghegediban SH , et al. Toxicity of doxorubicin on pig liver after chemoembolization with doxorubicin-loaded microspheres: a pilot DNA-microarrays and histology study[J]. Cardiovasc Intervent Radiol, 2013,36(1):204-212.
[5] Namur J, Pascale F, Maeda N , et al. Safety and efficacy compared between irinotecan-loaded microspheres HepaSphere and DC Bead in a model of VX2 liver metastases in the rabbit[J]. J Vasc Interv Radiol, 2015,26(7):1067-1075.
[6] Kaiser J, Kr?mer I . Loading profile of topotecan into polyvinyl alcohol microspheres (DC Bead TM) over a 7-day period [J]. J Oncol Pharm Pract, 2012,18(2):222-228.
[7] Fuchs K, Bize PE, Dormond O , et al. Drug-eluting beads loaded with antiangiogenic agents for chemoembolization: in vitro sunitinib loading and release and in vivo pharmacokinetics in an animal mo-del[J]. J Vasc Interv Radiol, 2014,25(3):379-387.
[8] Cui DC, Lu WL, Sa EA , et al. Poly (acrylic acid) microspheres loaded with lidocaine: preparation and characterization for arterial embolization[J]. Int J Pharm, 2012,436(1-2):527-535.
[9] Omidian H, Zohuriaan-Mehr MJ, Bouhendi H . Polymerization of sodium acrylate in inverse-suspension stabilized by sorbitan fatty esters[J]. Eur Polym J, 2003,39(5):1013-1018.
[10] Lewis AL, Gonzalez MV, Leppard SW , et al. Doxorubicin eluting beads-1: effects of drug loading on bead characteristics and drug distribution[J]. J Mater Sci Mater Med, 2007,18(9):1691-1699.
[11] Ahnfelt E, Sj?gren E, Hansson P , et al. In vitro release mechanisms of doxorubicin from a clinical bead drug-delivery system[J]. J Pharm Sci, 2016,105(11):3387-3398.
[12] Laurent A . Microspheres and nonspherical particles for embolization[J]. Tech Vasc Interv Radiol, 2007,10(4):248-256.
[13] Bendszus M, Klein R, Burger R , et al. Efficacy of trisacryl gela-tin microspheres versus polyvinyl alcohol particles in the preoperative embolization of meningiomas[J]. AJNR Am J Neuroradiol, 2000,21(2):255-261.
[14] Chua GC, Wilsher M, Young MP , et al. Comparison of particle penetration with non-spherical polyvinyl alcohol versus trisacryl gelatin microspheres in women undergoing premyomectomy uterine artery embolization[J]. Clin Radiol, 2005,60(1):116-122.
[15] Hu FQ, Liu LN, Du YZ , et al. Synjournal and antitumor activity of doxorubicin conjugated stearic acid-g-chitosan oligosaccharide po-lymeric micelles[J]. Biomaterials, 2009,30(36):6955-6963.
[16] Weng L, Le HC, Lin J , et al. Doxorubicin loading and eluting characteristics of bioresorbable hydrogel microspheres: in vitro study[J]. Int J Pharm, 2011,409(1):185-193.
[17] Flandroy P, Grandfils C, Collignon J , et al.( D, L) polylactide microspheres as embolic agent. A preliminary study[J]. Neuroradiology, 1990,32(4):311-315.
[18] Golzarian J, Weng L . Particle embolization: factors affecting arterial distribution[J]. J Vasc Interv Radiol, 2014,25(11):1773-1774.
[19] Guiu B, Schmitt A, Reinhardt S , et al. Idarubicin-loaded ONCOZENE drug-eluting embolic agents for chemoembolization of hepatocellular carcinoma: In vitro loading and release and in vivo pharmacokinetics[J]. J Vasc Interv Radiol, 2015,26(2):262-270.
[20] De BT, Plotkin S, Yu R , et al. An in vitro evaluation of four types of drug-eluting microspheres loaded with doxorubicin[J]. J Vasc Interv Radiol, 2016,27(9):1425-1431.
[21] Brown KT . Re: Fatal pulmonary complications after arterial embolization with 40-120 microm tris-acryl gelatin microspheres[J]. J Vasc Interv Radiol, 2004,15(1):887-888.
[22] Jordan O, Denys A, Baere T D . Comparative study of chemo-embolization loadable beads: in vitro drug release and physical properties of DC Bead and hepasphere loaded with doxorubicin and irinotecan[J]. J Vasc Interv Radiol, 2010,21(7):1084-1090.
[23] Ahnfelt E, Sj?gren E, Axén N , et al. A miniaturized in vitro release method for investigating drug-release mechanisms[J]. Int J Pharm, 2015,486(1-2):339-349.
[24] Gonzalez MV, Tang Y, Phillips GJ , et al. Doxorubicin eluting beads-2: methods for evaluating drug elution and in-vitro: in-vivo correlation[J]. J Mater Sci Mater Med, 2008,19(2):767-775.
[25] Zhao Z, Li J, Yang Y , et al. Preparation and characterization of sunitinib-loaded microspheres for arterial embolization[J]. J Chin Pharm Sci, 2014,23(8):558-564.
[26] Woo BH, Kostanski JW, Gebrekidan S , et al. Preparation, cha-racterization and in vivo evaluation of 120-day poly (d, l-lactide) leuprolide microspheres[J]. J Control Release, 2001,75(3):307-315.
[27] Altekruse SF, Henley SJ, Cucinelli JE , et al. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States[J]. Am J Gastroenterol, 2014,109(4):542-553.
[28] 姚红, 于雷, 钟丽华 , 等. DKK-1与肝脏恶性肿瘤的相关研究进展[J]. 现代生物医学进展, 2016,16(10):1962-1965.
[29] Llovet JM, Bisceglie AMD, Bruix J , et al. Design and endpoints of clinical trials in hepatocellular carcinoma[J]. J Natl Cancer Inst, 2008,100(10):698-711.
Outlines

/